David Crean
Founder & Managing Partner, Cardiff Advisory | Author, Dual Fluency
David Crean is founder and managing partner of Cardiff Advisory, a life sciences M&A and strategic advisory firm based in San Diego. He has spent more than 30 years at the intersection of science and capital, across investment banking, business development, mergers and acquisitions, and operating roles as a chief business officer.
Crean began as a scientist. He holds a PhD in biophysics and an MBA with a finance concentration, and he moved toward finance after watching technically strong programs succeed or fail on decisions about capital, strategy and transactions. His board service has included Histogen, where he was chairman and later lead independent director, Cenna Biosciences and Paracrine. He is the author of Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences, which argues that science and capital have to learn to speak to each other.
On Open Door Salon, alongside Phil Vanek of the International Society for Cell & Gene Therapy, he argued that investors want a de-risked asset and a manufacturing plan rather than a platform story, ranked capital, reimbursement and manufacturing cost in that order, and explained why deals announced at JPM begin many months before the headline.
Frequently Asked Questions About David Crean
Who is David Crean?
David Crean is founder and managing partner of Cardiff Advisory, a life sciences M&A and strategic advisory firm based in San Diego. He began as a scientist, holds a PhD in biophysics and an MBA with a finance concentration, and has spent more than 30 years in investment banking, business development, M&A and chief business officer roles.
What is David Crean an expert in?
David Crean’s expertise is the meeting point of life sciences and finance: mergers and acquisitions, investment banking and capital raising, business development, and the board decisions about how a company allocates limited capital across its programs.
How does David Crean think about what investors need from a biotech?
David Crean argues that investors underwrite evidence rather than ambition. On Open Door Salon he said, “Capital today is underwriting the evidence and the milestones, not some scientific ambition or something made up.” He ranks capital first, reimbursement second and manufacturing cost third.
What has David Crean written?
David Crean is the author of Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences. The book argues that science and capital have to learn to speak to each other, the theme of his career moving from the laboratory into finance.
On Open Door Salon
“Phil Vanek and David Crean on What Cell and Gene Therapy Investors Need to See”
Phil Vanek & David Crean · October 7, 2026
Episode page & show notes on Open Door Salon
In this episode
- What a seed-stage cell and gene therapy founder must show investors
- Show me the asset: why CMC cannot sit in the appendix
- Target product profile: write the label first
- Show me the data: AI, fabricated evidence and due diligence
- Capital, reimbursement and manufacturing, ranked
- Who pays: reimbursement in the US, UK and Europe
- Why deals announced at JPM start nine months earlier
- Hardening the supply chain, and cutting a program that works
Topics
Watch on Open Door Salon
Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.
Subscribe on Substack →